ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Dexamethasone

Also written as “dexamethasone”, “OTO-104” and “Dexycu”.

Its studies are mostly in Multiple Myeloma · Cataract · Macular Edema · Meniere Disease · Conjunctivitis, Allergic, led by 30 companies.

Drug pageDexamethasone: every studyMany companies study it; this page follows only the 92 they lead. All 1,797 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 6, 200392 company-led studies, 7 open or runningNext primary completion: Apr 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only200 open or runningphase 3since Mar 6, 2003Mar 6, 2003none ahead
Ocular Therapeutix100 open or runningphase 3since Jan 9, 2014Jan 9, 2014none ahead
Takedaits history only100 open or runningphase 4since May 30, 2017Jul 25, 2007none ahead
Oculisits history only50 open or runningphase 3since Sep 2, 2021Oct 16, 2019none ahead
Sun Pharmaceutical Industriesits history only50 open or runningphase 3since Dec 19, 2007Dec 19, 2007none ahead
Oncotherapeuticsits history only40 open or runningphase 2since Aug 26, 2008Aug 26, 2008none ahead
EyePoint Pharmaceuticalsits history only30 open or runningphase 4since Dec 13, 2021Dec 13, 2021none ahead
Hamad Medicalits history only32 open or runningphase 3since Nov 30, 2020Jan 12, 2010none ahead
Sanofiits history only33 open or runningphase 2since Oct 20, 2020Oct 20, 2020Apr 1, 2027phase 2 · NCT06356571
Alconits history only20 open or runningphase 4since Feb 29, 2008Feb 29, 2008none ahead

Also a collaborator on its studies: Karyopharm Therapeutics, AbbVie, Onyx Therapeutics, Abbott, Tigermed Consulting, Accelovance, ORA, Johnson & Johnson, Hoffmann-La Roche, Amgen, Novum Pharmaceutical Research Services, Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ocular Therapeutix only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2014First study: phase 3 study in PainFirst studyNCT02034019 · 247 enrolled · United States
  2. Feb 11, 2014Phase 2 study in Chronic Allergic ConjunctivitisNCT02062905 · 68 enrolled
  3. Mar 13, 2014Phase 3 study in Post-Surgical Ocular PainNCT02089113 · 241 enrolled
  4. May 13, 2015Phase 3 study in Chronic Allergic ConjunctivitisNCT02445326 · 73 enrolled
  5. Jun 4, 2015Phase 2 study in Dry Eye SyndromesNCT02468700 · 43 enrolled
  6. Feb 10, 2016Phase 3 study in Post-Surgical Ocular PainNCT02736175 · 438 enrolled
  7. Dec 2, 2016Phase 3 study in Chronic Allergic ConjunctivitisNCT02988882 · 86 enrolled
  8. Aug 7, 2019Phase 3 study in Conjunctivitis, AllergicNCT04050865 · 96 enrolled · United States
  9. Aug 27, 2020Phase 3 study in CataractNCT04539548 · 65 enrolled · United States
  10. Jun 1, 2021Early phase 1 study in HealthyNCT04945824 · 2 enrolled · United States
  11. Aug 6, 2023Named dexamethasoneINNProposed as its International Nonproprietary Name in WHO's List 129 · before, OTO-104

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
TriamcinoloneruleResearch Insightphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

All 10 Ocular Therapeutix leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04945824Healthy · United StatesEarly 1TerminatedNov 1, 20222
NCT04539548Cataract · United States3CompletedDec 21, 202365
NCT04050865Conjunctivitis, Allergic · United States3CompletedFeb 28, 202096
NCT02988882Chronic Allergic Conjunctivitis3CompletedApr 27, 201686
NCT02736175Post-Surgical Ocular Pain3CompletedMay 2016438
NCT02468700Dry Eye Syndromes2CompletedAug 201543
NCT02445326Chronic Allergic Conjunctivitis3CompletedAug 201573
NCT02089113Post-Surgical Ocular Pain3CompletedJan 2015241
NCT02062905Chronic Allergic Conjunctivitis2CompletedAug 201468
NCT02034019Pain · United States3CompletedDec 2014247

How it is read

Names in the registry

  • “Dexamethasone”, 94 entries
  • “dexamethasone”, 20 entries
  • “OTO-104”, 9 entries
  • “Dexycu”, 4 entries
  • “Dexamethasone Oral”, 3 entries

Codes read as this program: OCS01.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.